WEDNESDAY 15th JANUARY 2014 COMMENCING 10.30 AM
(UNTIL 4.00 PM APPROX)
AT THE ANGEL HOTEL, ABERGAVENNY, NP7 5EN

AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

Enclosure

5. Appraisal 1 – Full submission (WPAS)
   Abatacept (Orencia®) in combination with methotrexate for the
treatment of moderate to severe active polyarticular juvenile
idiopathic arthritis in paediatric patients 6 years of age and older who
have had an insufficient response to other disease-modifying anti-
rheumatic drugs (DMARDs) including at least one tumour necrosis
factor (TNF) inhibitor

To protect commercial confidentiality, the first appraisal will be conducted in private.
The final appraisal recommendation will be announced in public

6. Chairman’s report (verbal update)

7. AWMG Medicines Strategy for Wales

Appendices

8. Appraisal 2 – Full submission
   Atomoxetine (Strattera®) for the initiation of treatment in adults with
attention deficit hyperactivity disorder (ADHD)

Appendices

9. AWMG National Prescribing Indicators 2014-15

10. Appraisal 3 – Full submission
    Linaclotide (Constella®) for the symptomatic treatment of moderate
to severe irritable bowel syndrome with constipation in adults

Appendices
11. **Appraisal 4 – Full submission**

   Nalmefene (Selincro®) for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms and who do not require immediate detoxification. Nalmefene should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption. Nalmefene should be initiated only in patients who continue to have a high DRL two weeks after initial assessment.

12. **AWPAG update (draft minutes of December 2013 meeting)**

13. **CEPP/Therapeutics Priorities 2014**

14. **Date of next meeting:**

   Wednesday 19th February in Abergavenny